1.96
0.51%
-0.01
After Hours:
1.90
-0.06
-3.06%
Aeterna Zentaris Inc. stock is currently priced at $1.96, with a 24-hour trading volume of 11,719.
It has seen a -0.51% decreased in the last 24 hours and a -1.51% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.98 pivot point. If it approaches the $1.95 support level, significant changes may occur.
Previous Close:
$1.97
Open:
$1.96
24h Volume:
11,719
Market Cap:
$9.52M
Revenue:
$6.86M
Net Income/Loss:
$-23.37M
P/E Ratio:
-0.4206
EPS:
-4.66
Net Cash Flow:
$-15.13M
1W Performance:
+0.17%
1M Performance:
-1.51%
6M Performance:
+29.37%
1Y Performance:
-39.32%
Aeterna Zentaris Inc. Stock (AEZS) Company Profile
Name
Aeterna Zentaris Inc.
Sector
Industry
Phone
843 900 3223
Address
315 Sigma Drive, Summerville, SC
Aeterna Zentaris Inc. Stock (AEZS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-19-17 | Reiterated | Maxim Group | Buy |
May-10-17 | Reiterated | H.C. Wainwright | Buy |
May-01-17 | Reiterated | Maxim Group | Buy |
Jan-17-17 | Reiterated | Maxim Group | Buy |
Dec-02-15 | Reiterated | H.C. Wainwright | Buy |
Nov-24-15 | Reiterated | H.C. Wainwright | Buy |
Nov-23-15 | Reiterated | Maxim Group | Buy |
Apr-14-15 | Upgrade | H.C. Wainwright | Neutral → Buy |
Nov-06-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jul-17-14 | Initiated | H.C. Wainwright | Buy |
Jan-03-13 | Upgrade | MLV & Co | Hold → Buy |
Oct-09-12 | Initiated | Maxim Group | Buy |
Apr-02-12 | Downgrade | MLV & Co | Buy → Hold |
Jun-07-11 | Initiated | Oppenheimer | Outperform |
Apr-27-11 | Reiterated | Canaccord Genuity | Speculative Buy |
Nov-29-10 | Initiated | MLV Capital | Buy |
Feb-05-09 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jun-03-08 | Reiterated | Canaccord Adams | Buy |
Apr-14-08 | Reiterated | Canaccord Adams | Buy |
Oct-03-07 | Reiterated | Rodman & Renshaw | Mkt Outperform |
View All
Aeterna Zentaris Inc. Stock (AEZS) Latest News
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
GlobeNewswire Inc.
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
GlobeNewswire Inc.
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
GlobeNewswire Inc.
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
GlobeNewswire Inc.
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
GlobeNewswire Inc.
Aeterna Zentaris Inc. Stock (AEZS) Financials Data
Aeterna Zentaris Inc. (AEZS) Revenue 2024
AEZS reported a revenue (TTM) of $6.86 million for the quarter ending September 30, 2023, a +66.92% rise year-over-year.
Aeterna Zentaris Inc. (AEZS) Net Income 2024
AEZS net income (TTM) was -$23.37 million for the quarter ending September 30, 2023, a -77.44% decrease year-over-year.
Aeterna Zentaris Inc. (AEZS) Cash Flow 2024
AEZS recorded a free cash flow (TTM) of -$15.13 million for the quarter ending September 30, 2023, a -17.74% decrease year-over-year.
Aeterna Zentaris Inc. (AEZS) Earnings per Share 2024
AEZS earnings per share (TTM) was -$4.81 for the quarter ending September 30, 2023, a -75.55% decline year-over-year.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Cap:
|
Volume (24h):